company background image
1952

Everest MedicinesSEHK:1952 Stock Report

Last Price

HK$36.30

Market Cap

HK$10.8b

7D

17.1%

1Y

-58.8%

Updated

16 Jan, 2022

Data

Company Financials +
1952 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

1952 Stock Overview

Everest Medicines Limited, a clinical-stage biopharmaceutical company, focuses on licensing, developing, and commercializing therapies for addressing critical unmet medical needs in Greater China and other Asia Pacific markets.

Price History & Performance

Summary of all time highs, changes and price drops for Everest Medicines
Historical stock prices
Current Share PriceHK$36.30
52 Week HighHK$104.80
52 Week LowHK$30.00
Beta0
1 Month Change-10.37%
3 Month Change-18.06%
1 Year Change-58.75%
3 Year Changen/a
5 Year Changen/a
Change since IPO-50.10%

Recent News & Updates

Sep 26
A Look At The Fair Value Of Everest Medicines Limited (HKG:1952)

A Look At The Fair Value Of Everest Medicines Limited (HKG:1952)

How far off is Everest Medicines Limited ( HKG:1952 ) from its intrinsic value? Using the most recent financial data...

Shareholder Returns

1952HK BiotechsHK Market
7D17.1%7.5%3.2%
1Y-58.8%-32.6%-11.9%

Return vs Industry: 1952 underperformed the Hong Kong Biotechs industry which returned -32.6% over the past year.

Return vs Market: 1952 underperformed the Hong Kong Market which returned -11.9% over the past year.

Price Volatility

Is 1952's price volatile compared to industry and market?
1952 volatility
1952 Average Weekly Movement10.5%
Biotechs Industry Average Movement9.3%
Market Average Movement6.7%
10% most volatile stocks in HK Market13.1%
10% least volatile stocks in HK Market3.0%

Stable Share Price: 1952 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: 1952's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.

About the Company

FoundedEmployeesCEOWebsite
2017227Kerry Levan Blanchardhttps://www.everestmedicines.com

Everest Medicines Limited, a clinical-stage biopharmaceutical company, focuses on licensing, developing, and commercializing therapies for addressing critical unmet medical needs in Greater China and other Asia Pacific markets. It has a portfolio of eight clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal disease, and infectious diseases. Everest Medicines Limited was founded in 2017 and is headquartered in Shanghai, China.

Everest Medicines Fundamentals Summary

How do Everest Medicines's earnings and revenue compare to its market cap?
1952 fundamental statistics
Market CapCN¥8.79b
Earnings (TTM)-CN¥5.42b
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1952 income statement (TTM)
RevenueCN¥0
Cost of RevenueCN¥0
Gross ProfitCN¥0
ExpensesCN¥5.42b
Earnings-CN¥5.42b

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-18.26
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio5.3%

How did 1952 perform over the long term?

See historical performance and comparison

Valuation

Is Everest Medicines undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1952 (HK$36.3) is trading below our estimate of fair value (HK$156.16)

Significantly Below Fair Value: 1952 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 1952 is unprofitable, so we can't compare its PE Ratio to the Hong Kong Biotechs industry average.

PE vs Market: 1952 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1952's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1952 is good value based on its PB Ratio (1.2x) compared to the HK Biotechs industry average (3.1x).


Future Growth

How is Everest Medicines forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

45.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1952 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1952 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1952 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 1952's revenue (46.5% per year) is forecast to grow faster than the Hong Kong market (11.7% per year).

High Growth Revenue: 1952's revenue (46.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1952 is forecast to be unprofitable in 3 years.


Past Performance

How has Everest Medicines performed over the past 5 years?

-188.4%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: 1952 is currently unprofitable.

Growing Profit Margin: 1952 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 1952's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 1952's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1952 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54%).


Return on Equity

High ROE: 1952 has a negative Return on Equity (-76.25%), as it is currently unprofitable.


Financial Health

How is Everest Medicines's financial position?


Financial Position Analysis

Short Term Liabilities: 1952's short term assets (CN¥4.0B) exceed its short term liabilities (CN¥132.5M).

Long Term Liabilities: 1952's short term assets (CN¥4.0B) exceed its long term liabilities (CN¥434.9M).


Debt to Equity History and Analysis

Debt Level: 1952 has more cash than its total debt.

Reducing Debt: Insufficient data to determine if 1952's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1952 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 1952 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Everest Medicines's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1952's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 1952's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1952's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1952's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1952's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Kerry Levan Blanchard (65 yo)

1.92yrs

Tenure

Dr. Kerry Levan Blanchard, Ph D., M.D., is an Executive Director at Everest Medicines Limited since February 25, 2020 and serves as its Chief Executive Officer since February 2020. Dr. Blanchard is also a...


Leadership Team

Experienced Management: 1952's management team is considered experienced (2.4 years average tenure).


Board Members

Experienced Board: 1952's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Everest Medicines Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Everest Medicines Limited
  • Ticker: 1952
  • Exchange: SEHK
  • Founded: 2017
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: HK$10.771b
  • Shares outstanding: 296.72m
  • Website: https://www.everestmedicines.com

Number of Employees


Location

  • Everest Medicines Limited
  • Plaza 66
  • Tower 1, Units 6601-6606
  • Shanghai
  • 200040
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/16 10:04
End of Day Share Price2022/01/14 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.